Human ADRA2A Stable Cell Line - HEK293T

The ADRA2A gene encodes the α-2A adrenergic receptor, a member of the complex superfamily of G protein-coupled receptors (GPCRs). This cell-surface receptor is primarily activated by endogenous catecholamines—specifically norepinephrine and epinephrine—and functions as a fundamental regulatory component within both the central and peripheral nervous systems. Mechanistically, the α-2A adrenergic receptor predominantly couples with inhibitory G protein complexes known as Gi/o. Upon direct activation by appropriate ligands, it actively inhibits the enzymatic activity of adenylyl cyclase, thereby leading to a significant and measurable reduction in intracellular cyclic adenosine monophosphate (cAMP) production. Furthermore, activation of the ADRA2A receptor influences various other downstream intracellular signaling pathways, most notably exerting critical regulatory effects on voltage-gated calcium channels and inwardly rectifying potassium channels. This signaling cascade ultimately results in cellular hyperpolarization and a significant reduction in overall neuronal excitability. Physiologically, the ADRA2A receptor primarily functions as a presynaptic autoreceptor, providing a crucial negative feedback mechanism that inhibits the further release of norepinephrine from sympathetic nerve terminals.

HEK293T cells, originally derived from human embryonic kidney tissue and transformed with the SV40 large T antigen, possess unique and exceptional utility as a host expression system. By stably integrating the human ADRA2A gene sequence into the HEK293T cell genome, this optimized, engineered cell line ensures that functional α-2A adrenergic receptors maintain strictly consistent, sustained, and high-level cell-surface expression across numerous consecutive passages. This specific stable cell line product is now widely and routinely utilized across a broad spectrum of critical fields, including drug discovery and development, toxicology research, and various biomedical applications. The Human ADRA2A Stable Cell Line (HEK293T) has emerged as a critical experimental resource, significantly accelerating the modern drug discovery and development process—particularly in the development of therapeutics for primary hypertension, Attention Deficit Hyperactivity Disorder (ADHD), severe neuropathic pain, and various complex psychiatric disorders—thereby ultimately driving continuous advancements in the fields of targeted neuropharmacology and cardiovascular therapeutics.